sgmo stock price movement is being closely correlated with peer performance in the gene therapy niche. Cross-comparison models show Sangamo lagging average sector returns by 3% over the past month. Following the downgrade, the consensus from eight analysts covering Sangamo Therapeutics is for revenues of US$37m in 2024, implying a concerning 79% decline in sales compared to the last 12 months. Losses are predicted to fall substantially, shrinking 61% to US$0.50 per share. However, before this estimates update, the consensus had been expecting revenues of US$43m and US$0.48 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report Latest institutional ownership data indicates subtle accumulation, which could underpin sgmo stock price if long-term biotech growth narratives regain traction.